Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.36 -3.1%	$9.96	$6.02 ▼ $11.31	$2.02B	1.11	3.04 million shs	7.45 million shs
NAMS NewAmsterdam Pharma	$18.57 +0.7%	$18.72	$14.06 ▼ $27.29	$2.07B	-0.03	712,381 shs	1.24 million shs
RXRX Recursion Pharmaceuticals	$5.03 -6.9%	$4.88	$3.79 ▼ $12.36	$2.20B	0.84	15.71 million shs	46.48 million shs
TBPH Theravance Biopharma	$11.22 +4.6%	$10.00	$7.44 ▼ $11.82	$536.51M	-0.09	274,108 shs	1.36 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-3.11%	-7.33%	-11.36%	+19.08%	+51.46%
NAMS NewAmsterdam Pharma	+0.65%	+3.40%	+7.28%	-14.66%	-5.97%
RXRX Recursion Pharmaceuticals	-6.85%	0.00%	+14.58%	-13.43%	-42.58%
TBPH Theravance Biopharma	+4.57%	+5.55%	+22.62%	+21.56%	+33.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.4489 of 5 stars	4.4	2.0	4.2	2.0	1.7	0.6
NAMS NewAmsterdam Pharma	2.8429 of 5 stars	3.5	1.0	0.0	2.7	5.0	0.0
RXRX Recursion Pharmaceuticals	1.918 of 5 stars	3.2	1.0	0.0	2.7	1.7	0.6
TBPH Theravance Biopharma	1.9602 of 5 stars	3.3	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.89	Moderate Buy	$16.56	76.88% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	130.96% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	39.17% Upside
TBPH Theravance Biopharma	2.67	Moderate Buy	$16.60	47.95% Upside

Current Analyst Ratings Breakdown

Latest TBPH, BCRX, RXRX, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.35	N/A	N/A	($2.30) per share	-4.07
NAMS NewAmsterdam Pharma	$45.56M	45.76	N/A	N/A	$8.20 per share	2.26
RXRX Recursion Pharmaceuticals	$58.84M	34.75	N/A	N/A	$2.61 per share	1.93
TBPH Theravance Biopharma	$64.38M	8.71	N/A	N/A	$3.57 per share	3.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.19	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	-$1.18	N/A	32.06	N/A	-89.38%	-32.37%	-16.48%	8/4/2025 (Estimated)

Latest TBPH, BCRX, RXRX, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/8/2025	Q1 2025	TBPH Theravance Biopharma	-$0.11	-$0.27	-$0.16	-$0.27	$28.08 million	$15.39 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11
TBPH Theravance Biopharma	N/A	4.77	4.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
NAMS NewAmsterdam Pharma	89.89%
RXRX Recursion Pharmaceuticals	89.06%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
NAMS NewAmsterdam Pharma	20.84%
RXRX Recursion Pharmaceuticals	8.43%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.49 million	372.23 million	Optionable
TBPH Theravance Biopharma	359	50.00 million	46.55 million	Optionable

TBPH, BCRX, RXRX, and NAMS Headlines

Recent News About These Companies

Theravance Biopharma (NASDAQ:TBPH) Trading 5.7% Higher on Analyst Upgrade

3 hours ago | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst Upgrade

June 27 at 12:55 PM | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $25.00 at BTIG Research

June 27 at 11:16 AM | marketbeat.com

TBPH Theravance Biopharma, Inc. - Seeking Alpha

June 26 at 9:12 PM | seekingalpha.com

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA

June 26 at 6:00 AM | prnewswire.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded by Wall Street Zen to "Buy" Rating

June 21, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $11.33 Average PT from Analysts

June 20, 2025 | americanbankingnews.com

Jones Trading Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)

June 19, 2025 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up - Still a Buy?

June 17, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Hold" from Analysts

June 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from Analysts at Jones Trading

June 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - What's Next?

June 17, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 9, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 24,000 Shares

June 5, 2025 | marketbeat.com

Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 24,000 Shares of Stock

June 5, 2025 | insidertrades.com

Public Employees Retirement System of Ohio Takes $353,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 5, 2025 | marketbeat.com

Squarepoint Ops LLC Sells 51,783 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

June 5, 2025 | marketbeat.com

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

June 3, 2025 | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 52-Week High - Time to Buy?

June 3, 2025 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC

June 3, 2025 | marketbeat.com

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

June 2, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, BCRX, RXRX, and NAMS Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.36 -0.30 (-3.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.48 +0.12 (+1.29%)

As of 06/27/2025 07:55 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

NewAmsterdam Pharma NASDAQ:NAMS

$18.57 +0.12 (+0.65%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$18.86 +0.29 (+1.56%)

As of 06/27/2025 05:59 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.03 -0.37 (-6.85%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.05 +0.02 (+0.40%)

As of 06/27/2025 08:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Theravance Biopharma NASDAQ:TBPH

$11.22 +0.49 (+4.57%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.41 +0.19 (+1.69%)

As of 06/27/2025 05:26 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time